Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 98

Results For "NAL"

6627 News Found

Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
News | December 10, 2025

Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications

Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors


Fermenta Biotech to invest Rs. 110 crore for Dahej plant expansion
Biotech | December 10, 2025

Fermenta Biotech to invest Rs. 110 crore for Dahej plant expansion

This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing


Zydus and Formycon secure US and Canada partnership for Keytruda biosimilar
News | December 10, 2025

Zydus and Formycon secure US and Canada partnership for Keytruda biosimilar

Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories


Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
News | December 10, 2025

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors


Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
News | December 09, 2025

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones


Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma


WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
R&D | December 09, 2025

WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre

This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region


Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
Clinical Trials | December 09, 2025

Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership

The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination


Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access
News | December 09, 2025

Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access

Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares